Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Scientists Invited to Access New Cutting-edge Technology Platform

Published: Thursday, May 01, 2014
Last Updated: Thursday, May 01, 2014
Bookmark and Share
UCB announces that it has launched its ‘Technology Platform Access’, a collaboration programme for the discovery and development of novel antibodies against potential therapeutic targets.

Today medicine discovery is a sophisticated process that integrates scientific innovation with cutting-edge technology and through UCB’s ‘Technology Platform Access’, academic and research groups can apply to gain access to our new automated antibody discovery platform which is capable of rapidly generating, selecting, producing and evaluating new human antibody-based medicines for patients.

Commenting on the new programme, Dr Ismail Kola, Executive Vice President, UCB NewMedicines™, said “Partnerships between academic groups and industry are vital to the future of scientific discovery. We are hugely committed to seeking new ways of working and creating super-networks to advance medical research and improve health”. He added, “This programme offers the chance for groups to access our state-of-the-art technology as well as collaborate with our premier discovery team”.

In December 2013, UCB announced the successful completion of a $5.5 million investment in a new laboratory with cutting-edge robotic equipment for the fully automated discovery of antibodies. This has permitted us to greatly increase our antibody discovery capacity and coincides with the successful conclusion of a project to develop new technology to mine the natural repertoire of antibody sequence.

In conjunction with strong antibody engineering and expression capabilities, plus structural biology expertise, this represents a novel and efficient route to the generation of high quality antibodies, not only against human targets but also for the generation of research tools for proof-of-concept models.

UCB are now accepting proposals from academic and research groups for collaborative projects on antibody targets, using this antibody discovery platform at our immunology research centre of excellence facility in the UK.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UCB Announces US and EU Regulatory Filings for Brivaracetam
Major milestone for brivaracetam is latest step towards UCB goal of extending treatment choices for adult epilepsy patients with uncontrolled partial-onset seizures.
Tuesday, January 27, 2015
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
Strategic collaboration commences with three discovery programs in areas of high patient need.
Friday, April 04, 2014
UCB CEO to Chair IMI Board for a Second Term
Roch Doliveux to spearhead industry’s commitment to world’s biggest public-private partnership in biopharmaceutical research and innovation.
Wednesday, April 02, 2014
UCB and Sanofi Partner for Innovation in Immune-Mediated Diseases
Goal is to identify novel small molecule therapies to address a wide range of immune-mediated diseases.
Friday, March 14, 2014
UCB and Biogen Idec Enter Agreement
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s innovative therapies to patients in new markets.
Friday, January 31, 2014
Online Challenge to Find Next Generation of Breakthrough Medicines
UCB announces the global launch of its ‘Innovation Challenge’ which seeks to find rare phenotypes.
Tuesday, January 28, 2014
Multimillion Pound Investment in UK Life Sciences Research and Development
UCB invests over £3 million in new bespoke cutting-edge robotic platform for UK R&D HQ.
Wednesday, December 11, 2013
UCB Receives CHMP Positive Opinion for Cimzia in Active PsA
Positive opinion is supported by data from the RAPID™-PsA study.
Monday, October 28, 2013
Vectura and UCB to Collaborate and Share Expertise in Severe Inflammatory
Collaboration for the development of an innovative biologic immunomodulatory product in the area of severe inflammatory.
Tuesday, October 01, 2013
UCB Announces Third Research Collaboration with Harvard University
New Research Alliance project to focus on human microbiome to develop new therapeutic applications in immunology.
Wednesday, October 10, 2012
UCB Announces Start of C-EARLY™ Study for Cimzia® in RA
Phase III study to evaluate Cimzia® (certolizumab pegol) in adult patients with early, active, moderate to severe rheumatoid arthritis who have not been exposed to disease-modifying antirheumatic drugs.
Thursday, August 23, 2012
New Real World Clinical Data Showed Vimpat® (lacosamide) Effective in Achieving Seizure Control
At final follow-up 31.1% patients reported =50% seizures reduction and 9.8% were seizure free.
Friday, July 06, 2012
UCB to Showcase Immunology Portfolio at EULAR 2012
Data to be presented on certolizumab pegol, epratuzumab and CDP7851/AMG 785.
Thursday, July 05, 2012
UCB and Domainex Collaboration Provides Valuable Information on Cancer Drug Target
New structural information allowed UCB scientists to design a novel class of molecules which inhibit MEK.
Thursday, March 15, 2012
UCB CEO to Chair Innovative Medicines Initiative Board
Roch Doliveux confirms industry’s commitment to unique EU public-private partnership.
Monday, March 12, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!